Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Menicon Co Ltd MECNY OTC

Other OTC • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score
70/100
4/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Menicon Co Ltd (MECNY) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $88.63. It has a SharesGrow Score of 68/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Financials: revenue is $121.5B, +6.7%/yr average growth. Net income is $5.6B, growing at -0.3%/yr. Net profit margin is 4.6% (thin). Gross margin is 53.6% (+0.8 pp trend).

Balance sheet: total debt is $75.1B against $86.1B equity (Debt-to-Equity (D/E) ratio 0.87, moderate). Current ratio is 3.12 (strong liquidity). Debt-to-assets is 40.1%. Total assets: $187.3B.

SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 40/100 (Partial), Past 100/100 (Pass), Health 83/100 (Pass), Moat 90/100 (Pass), Future ?/100 (Fail), Income 30/100 (Fail).

MECNY SharesGrow Score Overview

70/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 75/100
Valuation — P/E, PEG, Forward PEG
GROWTH 40/100
Financials — average growth
PAST 100/100
strong — trend
HEALTH 83/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 90/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 30/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MECNY

✓
VALUE Pass
75/100
MECNY trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
40/100
MECNY: +6.7%/yr revenue is, -0.3%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✓
PAST Pass
100/100
MECNY: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
83/100
Balance sheet MECNY: Debt-to-Equity (D/E) ratio 0.87 (moderate), Current ratio is 3.12 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✓
MOAT Pass
90/100
MECNY: Gross margin is 53.6% (+0.8 pp trend), $107B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 90/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
30/100
MECNY: Net profit margin is 4.6%. thin (0-5%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range88.63-88.63
Volume100
Avg Volume (30D)36
Market Cap$107.5B
Beta (1Y)0.15
Share Statistics
EPS (TTM)4.63
Shares Outstanding$1.21B
IPO Date2021-10-01
CEOKoji Kawaura
Financial Highlights & Ratios
Revenue (TTM)$121.49B
Gross Profit$65.08B
EBITDA$18.48B
Net Income$5.62B
Operating Income$10.05B
Total Cash$42.05B
Total Debt$75.09B
Net Debt$33.04B
Total Assets$187.28B
Price / Earnings (P/E)19.1
Price / Sales (P/S)0.88
Analyst Forecast
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS58680V1061

Price Chart

Track all markets on TradingView
MECNY
Menicon Co Ltd ↗  ·  Other OTC
Healthcare • Medical - Instruments & Supplies

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message